Bend Bioscience, a company involved in drug delivery innovation, development, and manufacturing, opened its state-of-the-art pharmaceutical process and manufacturing science facility. The facility is approximately 15,000 sq.-ft. and is designed to accommodate process identification, development, scale-up and production of high-quality materials to support clinical trials.

Equipped to uphold good manufacturing practice (GMP) standards, and a total of seven state-of-the-art processing suites, the design has the capability and capacity to handle a diverse range of client needs. To maintain the highest quality standards of a multi-product facility it incorporates a HEPA-filtered, single pass, unidirectional HVAC system, including separate ingress and egress airlocks on each processing suite. The facility includes a continuously monitored building automation system with electronic data capture as well as an onsite GMP Quality Control lab.

The company said that the versatility of Bend Bioscience’s advanced suites, including solvent-capable spray drying and low humidity capabilities provides flexibility for tailored solutions to meet the unique needs of each client.

“This new facility seamlessly complements our existing R&D Innovation Lab, and we’re excited to now be able to make these innovations a reality and take our clients’ programs to the next level with support of further process scale-up and GMP manufacturing,” said Dan Dobry, chief strategy officer of Bend Bioscience, and its parent company CoreRx.”Bend Bioscience invites interested parties, including potential clients, collaborators and partners, to visit its new facility and discover the possibilities it holds for the future of their most important programs.”